Novo Nordisk's oral version of its GLP-1 drug is now cleared for obesity treatment in Bahrain, GCC Business News reports.
Recap by typeshit. Post by GCC Business News on X.
The MFDS approval rests on SURPASS-CVOT, where Mounjaro matched Trulicity on heart events in 13,000+ patients but did not prove superior.
Inside Retail Asia looks at skincare and aesthetic treatments brands are building for facial volume loss after rapid weight loss.
The actor told an interviewer people can take Ozempic carefree, while stressing that nothing replaces actually working out.
CFO MV Narasimham says the company still expects to ship 6 to 7 million pens across 10 approved markets between November and March, with Canada taking most of them.
The law firm Mintz rounds up recent FDA policy shifts and agency actions affecting medical and life sciences companies this month.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
Loading…